Pricing Log in Create free account
Friday 6 November 2026 Export AUPH’s income statement to Excel — free account

Aurinia Pharmaceuticals Inc

AUPH Healthcare Biotechnology

Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.

Revenue
+13.9%
EPS
0.00%
Free cash flow
+4.41%
Total debt
−30.0%

Quarter to September 2026, against a year earlier

16.32 0.11 +0.68%
Market cap
$2.2B
P/E
6.8×
Fwd P/E
17.6×
Dividend yield
—
F-score
8/9
Altman Z
7.86
Beneish M
−0.88
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 25.14
Sold, $m 0.55
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 1 — — 1 — — — — — —
Sell — — — — — — — — 1 1 — —
Insider Ownership 10.84%

Capital & Financial Ratios $m

Size
Market Cap 2,170.00
Revenue ttm 321.74
Net income ttm 314.27
Free cash flow ttm 177.03
Net debt Q (447.85)
Valuation
P/E 6.78
Forward P/E 17.60
Price / sales 6.72
Forward P/S Powerpack
Price / FCF 12.22
Price / book 3.29
Financial health
Current ratio Q 6.12 (at or above 1.5: strong)
Debt / equity Q 0.06 (at or below 0.5: strong)
Interest coverage Q 39.33
Growth
Revenue growth Q +13.93% (above 0%: growing)
Operating income growth Q +11.16% (above 0%: growing)
EPS, this year −53.14% (below 0%: weak)
EPS, next year A +19.59% (at or above 15%: strong)
Revenue, next year A +16.69% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A −11.67% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.3×, against a ten-year median of 29.6×; over the ten years it ranged from 1.9× in 2022 to 13,100× in 2020.
P/S against its own 10 years 20.35%
10-year low 10-year high
P/B against its own 10 years 37.29%
10-year low 10-year high
EV/Sales against its own 10 years 20.10%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 350 358 398 487
Receivables 24 37 41 47
Inventory 40 39 46 44
Other 1 1 1 4
425 447 492 588
2023 2024 2025 Q'26
Payables 4 5 3 3
ST’ Debt — — — —
Other 2 2 2 1
77 98 94 96

Compound Annual Growth %

10y 5y 3y
Sales 103.27% 41.38% 28.30%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 40.09% 7.35% 12.76%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.20 Actual 0.23

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.21 0.26 Beat by 0.05
Q1 FY26 0.18 0.25 Beat by 0.07
Q2 FY26 0.19 0.28 Beat by 0.09
Q3 FY26 0.20 0.23 Beat by 0.03
Q4 FY26 0.19 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.25 0.28 0.23 — —
’25 0.16 0.16 0.23 1.53 2.07
’24 (0.07) 0.01 0.10 0.01 0.04
’23 (0.18) (0.08) (0.09) (0.19) (0.54)
’22 (0.27) (0.25) (0.06) (0.18) (0.76)
’21 (0.40) (0.37) (0.39) (0.25) (1.40)
’20 (0.23) (0.26) (0.28) (0.06) (0.87)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 78 83 84 — —
’25 62 70 73 77 283
’24 50 57 68 60 235
’23 34 41 55 45 176
’22 22 28 56 28 134
’21 1 7 15 23 46
’20 0 0 0 50 50
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 33 53 46 — —
’25 1 44 44 46 136
’24 (19) 16 17 30 44
’23 (32) (3) (13) 14 (33)
’22 (47) (28) (15) 10 (80)
’21 (54) (38) (40) (26) (158)
’20 (23) (22) (28) 3 (70)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 33 53 46 — —
’25 1 44 44 46 135
’24 (19) 16 17 30 44
’23 (32) (3) (13) 14 (34)
’22 (47) (28) (15) 10 (80)
’21 (54) (38) (40) (26) (158)
’20 (23) (22) (32) 2 (75)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 0 0 0 50 46 134 176 235 283 322 +127.6% 330 388 447 +16.5%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 97.61 95.77 91.94 87.99 88.46 90.62 (11.5) pt
EBT (23) (71) (64) (88) (103) (180) (106) (77) 7 114 167 n/m
EBT margin, % (13,465.32) (16,935.89) (13,833.05) (27,748.74) (205.06) (395.15) (79.35) (44.14) 3.17 40.33 51.94 +13,505.7 pt
Net income (23) (71) (64) (88) (103) (181) (108) (78) 6 287 314 n/m
Per share, $
Per share, $ Revenue 0.00 0.01 0.01 0.00 0.42 0.35 0.94 1.23 1.64 2.11 2.41 +96.2%
Earnings (0.66) (0.92) (0.76) (0.95) (0.87) (1.40) (0.76) (0.54) 0.04 2.14 2.39 n/m
Cash flow (0.53) (0.54) (0.61) (0.68) (0.59) (1.22) (0.56) (0.23) 0.31 1.01 1.33 n/m
Capex 0.88 0.00 0.00 0.00 (0.05) 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow 0.35 (0.54) (0.61) (0.68) (0.64) (1.22) (0.56) (0.24) 0.31 1.01 1.33 +12.4%
Book value 1.02 2.15 1.33 3.21 3.44 3.70 2.86 2.64 2.64 4.33 4.93 +17.4%
Shares, m 35 77 85 93 118 129 142 143 143 134 133 +16.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 199.56 7.35 6.78 20.7
P/S 438.51 892.47 1,248.84 5,926.62 32.69 64.88 6.29 7.13 5.46 7.57 6.72 863.0
P/B 2.11 2.25 5.14 6.31 4.02 6.18 2.08 3.31 3.40 3.69 3.29 3.8
EV/Sales 209.33 477.49 977.01 4,965.10 24.86 54.79 3.42 5.57 4.19 6.35 5.33 672.8
EV/FCF 2.92 (4.85) (8.75) (24.79) (16.52) (15.81) (5.75) (28.58) 22.33 13.27 9.69 (6.7)
Cash, $m
Cash, $m Operating cash flow (19) (41) (52) (64) (70) (158) (80) (33) 44 136 177 n/m
Capex 31 0 0 0 (6) 0 0 (1) 0 0 0 n/m
Free cash flow 12 (41) (52) (64) (75) (158) (80) (34) 44 135 177 +30.4%
Balance, $m
Balance, $m Working capital 33 167 126 304 387 473 396 348 349 398 492 +31.7%
Net debt (40) (173) (126) (306) (392) (460) (384) (275) (300) (346) (448) +27.2%
Shareholders’ equity 36 166 113 299 408 479 405 378 377 581 658 +36.2%
Returns, %
Returns, % ROA (51.44) (57.36) (38.20) (37.60) (26.06) (35.94) (21.33) (15.31) 1.05 44.11 46.45 +95.6 pt
ROIC 0.00 0.00 0.00 0.00 (395.10) (590.76) (330.89) (50.58) (7.28) 30.35 42.95 +30.3 pt
ROE (83.33) (70.20) (46.08) (42.99) (29.07) (40.81) (24.46) (19.92) 1.52 59.91 61.42 +143.2 pt
People
People Employees 20 33 39 62 294 300 300 300 130 128 — +22.9%
Revenue/emp, $m 0.01 0.01 0.01 0.01 0.17 0.15 0.45 0.59 1.81 2.21 — +85.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Aurinia Pharmaceuticals Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ADMA ADMA Biologics Inc $3.0B 16.7× 14.0× +5.12% (above 0%: growing) +46.67% (above 0%: growing) +1,709.49% (above 0%: growing) 70.81% 48.02% Compare
VCEL Vericel Corporation $2.7B 77.8× 72.9× +26.47% (above 0%: growing) +180.00% (above 0%: growing) −19.39% (below 0%: shrinking) 73.34% 14.27% Compare
PVLA Palvella Therapeutics, Inc. $2.3B — (loss-making) — (loss-making) −99.09% (below 0%: shrinking) n/m −136.38% (below 0%: shrinking) 100.00% 0.00% Compare
CLDX Celldex Therapeutics, Inc. $2.2B — (loss-making) — (loss-making) −96.83% (below 0%: shrinking) n/m −35.45% (below 0%: shrinking) 100.00% (366,468.18%) Compare
LKFT Lakefront Biotherapeutics - Sponsored ADR $2.2B — (loss-making) — (loss-making) −95.35% (below 0%: shrinking) +198.85% (above 0%: growing) +18.22% (above 0%: growing) 25.95% (982.91%) Compare
AUPH Aurinia Pharmaceuticals Inc $2.2B 6.8× 17.6× +13.93% (above 0%: growing) 0.00% +4.41% (above 0%: growing) 90.08% 40.74%
VERA Vera Therapeutics, Inc. $2.2B — (loss-making) — — n/m −82.47% (below 0%: shrinking) 0.00% 0.00% Compare
IMNM Immunome, Inc. $2.1B — (loss-making) — (loss-making) +69.84% (above 0%: growing) n/m −26.96% (below 0%: shrinking) 100.00% 0.00% Compare
BHVN Biohaven Ltd. $2.1B — (loss-making) — (loss-making) +131.43% (above 0%: growing) n/m +26.55% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $2.2B — — +5.12% +180.00% −23.17% 72.08% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 21 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 5.86m 17.55m 115.33
2024 6.42m 7.62m 64.93
2023 10.57m 14.92m 65.00
2022 8.84m (8.90m) 31.24
2021 1.24m 16.34m 165.37

Ownership

Directors and executive officers, together 10.40%
Tang Capital Management, LLC 9.40%
Kevin Tang 9.40%
BlackRock, Inc. 6.90%
ILJIN 5.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Aurinia Pharmaceuticals Inc (AUPH) Latest News

6 Nov

Impact 3 · · Simply Wall St.

30 Oct

Impact 3 · · Associated Press
Impact 3 · · Business Wire

27 Oct

Impact 3 · · Zacks

16 Sep

Impact 4 ·

28 Aug

Impact 3 ·

20 Aug

Impact 4 ·

19 Aug

Impact 4 · · Stocktwits
Impact 3 ·

6 Aug

Impact 3 ·

6 Jul

Impact 3 ·

4 Jun

Impact 4 · · Business Wire

19 May

Impact 4 · · TMX Newsfile

9 May

Impact 4 · · Simply Wall St.

7 May

Impact 4 · · Zacks
Impact 4 · · Business Wire

30 Mar

Impact 4 · · Business Wire

29 Mar

Impact 4 · · Simply Wall St.

23 Mar

Impact 4 · · Investor's Business Daily
Impact 4 · · Business Wire
Impact 3 · · Business Wire

2 Mar

Impact 4 · · Simply Wall St.

1 Mar

Impact 4 · · Insider Monkey

26 Feb

Impact 4 · · Moby
Impact 4 ·
Impact 4 · · MarketBeat
Impact 4 · · Simply Wall St.
Impact 4 · · Zacks
Impact 4 · · Associated Press FinanceSimply Wall St.Associated Press FinanceMT Newswires
Impact 4 · · Business Wire

AUPH metrics, ten years each

stockrow.com/AUPH · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com